Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Gattex Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Gattex (teduglutide) Coverage

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and clinical coverage for Gattex (teduglutide) in adult patients with short bowel syndrome who are dependent on parenteral nutritional support. It also specifies dosing, administration, contraindications, warnings, and supply information.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGattex (teduglutide) Coverage
    Policy CodePolicy N/A
    Change TypeArchivedno material changes
    Effective DateApr 22, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for adults with short bowel syndrome who depend on parenteral nutritional support.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults with SBSCovered indication
    0.05 mg/kgSubcutaneous dose
    CCr <50Dose-reduction threshold
    4 mg vialAvailable strength
    Archived

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy status

    Coverage Criteria

    Initial Gattex Therapy

    Covered when all of the following are met:

    Covered indication

    • The patient is an adult with short bowel syndrome and is dependent on parenteral nutritional support.

      Prior authorization criterion

    Do not use Gattex in patients with active gastrointestinal malignancy or colorectal polyps.

    Gattex must be administered subcutaneously. Intramuscular and intravenous administration are not permitted under this policy.

    Clinical Parameters

    Creatinine clearance
    ThresholdCreatinine clearance less than 50 mL/min
    Dose adjustmentUse one-half of the usual dose
    Standard dose0.05 mg/kg subcutaneously

    Provider Actions and Coverage Risks

    Prior Authorization

    Submit prior authorization for eligible adult SBS patients

    Prior authorization is required for treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral nutritional support.

    Denial Risk

    Confirm the covered indication

    Coverage may be denied when the patient does not have short bowel syndrome, is not an adult, or is not dependent on parenteral nutritional support.

    • Confirm that the patient is an adult.
    • Confirm short bowel syndrome and dependence on parenteral nutritional support.

    Clinical Background

    Gattex (teduglutide) is a recombinant DNA-derived glucagon-like peptide-2 (GLP-2) analog. GLP-2 inhibits gastric acid secretion, increases portal blood flow, and binds to enteroendocrine cells to promote local release of mediators such as IGF-1 and nitric oxide.

    Key Definition

    Short bowel syndrome (SBS)
    PopulationAdults
    ConditionShort bowel syndrome (SBS)
    Support requirementDependence on parenteral nutritional support

    Initial Therapy Criteria

    Initial Therapy

    Prior authorization is required when all of the following are met:

    Initial therapy criteria

    • ALL of the following

      • The patient is an adult.
      • The patient has short bowel syndrome.
      • The patient is dependent on parenteral nutritional support.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGattex (teduglutide) Coverage
    Policy CodePolicy N/A
    Change TypeArchivedno material changes
    Effective DateApr 22, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for adults with short bowel syndrome who depend on parenteral nutritional support.
    SourceLink
    On This Page
    Coverage CriteriaClinical ParametersProvider Actions and Coverage RisksClinical BackgroundKey DefinitionInitial Therapy Criteria
    Denial Risk

    Screen for malignancy and colorectal polyps

    Avoid treatment in patients with active gastrointestinal malignancy or colorectal polyps.

    Billing Rule

    Use the required subcutaneous route

    Gattex must be administered subcutaneously. Do not administer it intramuscularly or intravenously.